US FDA accepts and grants priority review to sNDA for BRAFTOVI in combination with ERBITUX to treat BRAFV600E-mutant metastatic colorectal cancer after prior therapy

Image: Pfizer world headquarters in Manhattan, New York. Photo: courtesy of Coolcaesar.